Tech Cohort 2018
MadeComfy - Sabrina Bethunin
MadeComfy is a fully integrated property management solution for Short-Term Rental that combines property management with hospitality. For property owners and property investors, MadeComfy offers the opportunity to get maximised income for their properties, hassle-free. Learn more about MadeComfy here.
Pax Republic - Barbara Sharp
Pax Republic builds technology to harness large group emotional intelligence to enable well-informed decisions. Their lead product, C-Sight™, is the world’s first preventative culture risk solution. It helps CEOs and company directors prevent #MeToo-style culture risks from causing harm to people and corporate reputation. Learn more about Pax Republic here.
Place Score - Kylie Legge
Place Score is the first ‘place experience’ measurement platform that lets communities share what they most care about, rate their own places, and in doing so help governments and developers prioritise investment in neighbourhoods, town centres and workplaces. Learn more about Place Score here.
RIP Global - Melissa Gollan
RIP Global is a secure clean data platform designed to collect the complete accounting data packet from the customer at the source of purchase. Patent protected and globally unique, RIP Global has ripped the receipts and invoices out of the hands of their customers - the #1 most hated task performed by every business. Learn more about RIP Global here.
The Volte - Bernadette Olivier
The Volte is the 'Airbnb of Fashion' allowing individuals to borrow and lend designer fashion. Previously individuals had no ability to earn income from their designer purchases. The Volte allows lenders to rent their items with peace of mind due to its integrated services. Learn more about The Volte here.
Biotech and Life Sciences Pilot Cohort 2018
Dimerix - Kathy Harrison
Dimerix has a platform technology which identifies receptor- receptor dimers, particularly GPCR's. This technology has been used to understand complex pharmacology, and also used to identify DMX-200 the lead clinical program. DMX-200 is an adjunct therapy for use in chronic kidney disease, first indications are the rare disease focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy. Phase 2a proof of concept data has been received and further Phase 2 trials. will commence shortly. Learn more about Dimerix here.
Prota Therapeutics - Mimi Tang
Prota Therapeutics is a newly established Australian private company developing immunotherapy based treatments for food allergy. The company’s lead product under development is a treatment for the most common cause of life-threatening anaphylaxis, peanut allergy, and is based on technology spun out of the Murdoch Children's Research Institute.